SCHEMBL9608321

SCHEMBL9608321

Cc1cccc(-c2ccc(Cn3cc4c(=O)n(C)c(=O)n(CC(C)C)c4c3Nc3ccccc3)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 7/20 0.45
PDE1A P54750 6/20 0.45
PDE1C Q14123 6/20 0.45
PDE2A O00408 4/20 0.42
SLC16A1 P53985 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
HPGD P15428 2/20 0.36
PDE4A P27815 2/20 0.35
BRD4 O60885 1/20 0.35
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2451829 0.91 PDE1B (0.54) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL9608326 0.89 PDE1B (0.44) PDE1BPDE1APDE1CPDE2AALDH1A1
SCHEMBL8513322 0.88 PDE1B (0.46) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL2455782 0.82 PDE1B (0.42) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL2452774 0.82 PDE1B (0.41) PDE1BPDE1APDE1CPDE2AALDH1A1
SCHEMBL2454552 0.82 PDE1A (0.46) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL2460367 0.81 PDE1A (0.45) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL9608338 0.80 PDE1B (0.44) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL2456668 0.80 PDE1B (0.54) PDE1BPDE2AALDH1A1KDM4EGAA
SCHEMBL3389822 0.76 PDE1B (0.43) PDE1BPDE1APDE1CPDE2ASLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353556-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-12-10 US disclosed
US-8927556-B2 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds INTRA-CELLULAR THERAPIES, INC. (US) 2015-01-06 US disclosed
US-20120136013-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES. INC. 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353556-A1 ORGANIC COMPOUNDS CYP2C9, TPMT, CYP2C19 PDE1B 4863/4885PDE1A 4874/4885PDE1C 4862/4885
US-20120136013-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.